A Clinical Study for the Treatment of Parkinson's Disease with Integrated Shi Shi Tonifying Kidney Pill and Xingnao Kaiqiao Acupuncture

注册号:

Registration number:

ITMCTR1900002280

最近更新日期:

Date of Last Refreshed on:

2019-04-14

注册时间:

Date of Registration:

2019-04-14

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

石氏益肾丸结合”醒脑开窍“针刺法治疗帕金森氏病的临床研究

Public title:

A Clinical Study for the Treatment of Parkinson's Disease with Integrated Shi Shi Tonifying Kidney Pill and Xingnao Kaiqiao Acupuncture

注册题目简写:

English Acronym:

研究课题的正式科学名称:

石氏益肾丸结合“醒脑开窍”针刺法治疗帕金森氏病的临床研究

Scientific title:

A Clinical Study for the Treatment of Parkinson's Disease with Integrated Shi Shi Tonifying Kidney Pill and Xingnao Kaiqiao Acupuncture

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900022500 ; ChiMCTR1900002280

申请注册联系人:

卞金玲

研究负责人:

石学敏 卞金玲

Applicant:

Jinling Bian

Study leader:

Xuemin Shi; Jinling Bian

申请注册联系人电话:

Applicant telephone:

+86 18602219443

研究负责人电话:

Study leader's telephone:

+86 18602219443

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yinleyuan66@aliyun.com

研究负责人电子邮件:

Study leader's E-mail:

yinleyuan66@aliyun.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

天津市南开区鞍山西道314号

研究负责人通讯地址:

天津市南开区鞍山西道314号

Applicant address:

314 AnShan Road West, NanKai District, Tianjin, China

Study leader's address:

314 AnShan Road West, NanKai District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津中医药大学附属第一医院

Applicant's institution:

First Affiliated Hospital of Tianjin Medical University of TCM

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013/8/26 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

深圳市金方针略科技有限责任公司

Primary sponsor:

ShenZhen JinFangZhenLue Technology Ltd. Co.

研究实施负责(组长)单位地址:

深圳市南山区蛇口街道太子路1号新时代广场第14层A-L单元C08

Primary sponsor's address:

Room C08, Unit A-L, 14th Floor, New Times Square, 1 Taizi Road, Shekou Street, NanShan District, ShenZhen, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

深圳

Country:

China

Province:

Tianjin

City:

Shenzhen

单位(医院):

深圳市金方针略科技有限责任公司

具体地址:

南山区蛇口街道太子路1号新时代广场第14层A-L单元C08

Institution
hospital:

ShenZhen JinFangZhenLue Technology Ltd. Co.

Address:

1 Taizi Road, Shekou Street, NanShan District

经费或物资来源:

深圳市金方针略科技有限责任公司

Source(s) of funding:

ShenZhen JinFangZhenLue Technology Ltd. Co.

研究疾病:

帕金森氏病

研究疾病代码:

Target disease:

Parkinson’s disease

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

寻求石氏益肾丸结合醒脑开窍针刺法治疗帕金森氏病的临床证据,明确针刺治疗帕金森氏病的量效关系。

Objectives of Study:

To find out the clinical evidence for the integrated Shi Shi Tonifying Kidney Pill and "XingNaoKaiQiao" Acupuncture Therapy Treatment for Parkinsons disease, and the dose-effect relationship of acupuncture manipulation for Parkinsons disease.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1) 符合英国帕金森病协会脑库的PD诊断标准; (2) 改良Hoehn-Yahr(H-Y)分级属于1-4级; (3) 年龄在40至80岁之间; (4) PD病程≥6个月; (5) 自愿参加本研究,接受相关检查和治疗,愿意完成相关量表的评定并签署知情同意书者。

Inclusion criteria

(1) diagnosis of Parkinsons disease according to the UK Parkinsons Disease Society Brain Bank Clinical Diagnostic Criteria; (2) the Hoehn-Yahr (H&Y) stage belongs to 1-4; (3) aged between 40 and 80 years; (4) the course of PD is ≥6 months; (5) those who voluntarily participate in the study, receive relevant examinations and treatments, and sign informed consent.

排除标准:

(1)急性期脑梗死患者; (2)妊娠期或哺乳期妇女、育龄期妇女未采取避孕措施; (3)合并严重肝、肾功能损害、精神疾患或造血系统疾病; (4)针刺穴位或穴位附近皮肤有感染者; 注:凡符合上述任何一条的患者,即应予以排除。

Exclusion criteria:

(1) acute cerebral infarction patients; (2) women who were pregnant or lactating and women of child-bearing age did not take contraceptive measures; (3) complicated with serious liver and kidney dysfunction, mental illness or hematopoietic system diseases; (4) the infection of the skin near the acupuncture point or acupoint; Note: any patient who meets any of the above shall be excluded.

研究实施时间:

Study execute time:

From 2019-09-01

To      2022-08-31

征募观察对象时间:

Recruiting time:

From 2019-09-01

To      2020-08-31

干预措施:

Interventions:

组别:

分散治疗组

样本量:

60

Group:

Scattered treatment group

Sample size:

干预措施:

“醒脑开窍”针刺法

干预措施代码:

Intervention:

"Xing Nao Kai Qiao" Acupuncture Therapy

Intervention code:

组别:

集中治疗组

样本量:

60

Group:

Intensive treatment group

Sample size:

干预措施:

石氏益肾丸加“醒脑开窍”针刺法

干预措施代码:

Intervention:

Integrated Shi Shi Tonifying Kidney Pill and “Xing Nao Kai Qiao" Acupuncture Therapy

Intervention code:

样本总量 Total sample size : 120

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津中医药大学第一附属医院

单位级别:

三级甲等医院

Institution/hospital:

Tianjin First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

中医主症积分

指标类型:

次要指标

Outcome:

Traditional Chinese medicine syndrome

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

步行20米所需时间和步数

指标类型:

次要指标

Outcome:

The time and number of steps required to walk 20 meters

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

帕金森病生活质量调查(PDQ-39)

指标类型:

次要指标

Outcome:

39-item Parkinson Disease Question (PDQ-39)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抑郁自评量表

指标类型:

次要指标

Outcome:

SDS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

帕金森病睡眠量表

指标类型:

次要指标

Outcome:

PDSS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

统一帕金森病评分量表

指标类型:

主要指标

Outcome:

Unified Parkinson Disease Rating Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 40
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者应用最小不平衡指数的随机方法。

Randomization Procedure (please state who generates the random number sequence and by what method):

The researchers applied the stochastic method of minimum unbalance index.

盲法:

open

Blinding:

open

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

本课题将于课题结题后使用ResMan进行原始数据共享, http://www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Our group will use ResMan to share raw data in the end of this project, http://www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据包括原始记录、病例记录表等数据,采用ResMan数据库

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data includes raw records, case records , et al. The ResMan database will be used.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above